Larazotide acetate regulates epithelial tight junctions in vitro and in vivo

Shobha Gopalakrishnan, Malarvizhi Durai, Kelly Kitchens, Amir P. Tamiz, Robert Somerville, Mark Ginski, Blake M. Paterson, Joseph A. Murray, Elena F. Verdu, Sefik S. Alkan, Niranjan Pandey

Research output: Contribution to journalArticle

Abstract

Tight junctions (TJs) control paracellular permeability and apical-basolateral polarity of epithelial cells, and can be regulated by exogenous and endogenous stimuli. Dysregulated permeability is associated with pathological conditions, such as celiac disease and inflammatory bowel disease. Herein we studied the mechanism by which larazotide acetate, an 8-mer peptide and TJ regulator, inhibits the cellular changes elicited by gliadin fragments, AT-1002, and cytokines. Previously, we demonstrated that AT-1002, a 6-mer peptide derived from the Vibrio cholerae zonula occludens toxin ZOT, caused several biochemical changes in IEC6 and Caco-2 cells resulting in decreased transepithelial electrical resistance (TEER) and increased TJ permeability. In this study, larazotide acetate inhibited the redistribution and rearrangement of zonula occludens-1 (ZO-1) and actin caused by AT-1002 and gliadin fragments in Caco-2 and IEC6 cells. Functionally, larazotide acetate inhibited the AT-1002-induced TEER reduction and TJ opening in Caco-2 cells. Additionally, larazotide acetate inhibited the translocation of a gliadin 13-mer peptide, which has been implicated in celiac disease, across Caco-2 cell monolayers. Further, apically applied larazotide acetate inhibited the increase in TJ permeability elicited by basolaterally applied cytokines. Finally, when tested in vivo in gliadin-sensitized HLA-HCD4/DQ8 double transgenic mice, larazotide acetate inhibited gliadin-induced macrophage accumulation in the intestine and preserved normal TJ structure. Taken together, our data suggest that larazotide acetate inhibits changes elicited by AT-1002, gliadin, and cytokines in epithelial cells and preserves TJ structure and function in vitro and in vivo.

Original languageEnglish (US)
Pages (from-to)86-94
Number of pages9
JournalPeptides
Volume35
Issue number1
DOIs
StatePublished - May 2012

Fingerprint

Tight Junctions
Gliadin
Caco-2 Cells
Permeability
Acoustic impedance
Cytokines
Celiac Disease
Peptides
Electric Impedance
Epithelial Cells
Macrophages
AT-1001
In Vitro Techniques
Actins
Inflammatory Bowel Diseases
Monolayers
Transgenic Mice
Intestines

Keywords

  • Actin
  • Celiac disease
  • Gliadin
  • Permeability inducer
  • Tight junction
  • ZO-1

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Gopalakrishnan, S., Durai, M., Kitchens, K., Tamiz, A. P., Somerville, R., Ginski, M., ... Pandey, N. (2012). Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides, 35(1), 86-94. https://doi.org/10.1016/j.peptides.2012.02.015

Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. / Gopalakrishnan, Shobha; Durai, Malarvizhi; Kitchens, Kelly; Tamiz, Amir P.; Somerville, Robert; Ginski, Mark; Paterson, Blake M.; Murray, Joseph A.; Verdu, Elena F.; Alkan, Sefik S.; Pandey, Niranjan.

In: Peptides, Vol. 35, No. 1, 05.2012, p. 86-94.

Research output: Contribution to journalArticle

Gopalakrishnan, S, Durai, M, Kitchens, K, Tamiz, AP, Somerville, R, Ginski, M, Paterson, BM, Murray, JA, Verdu, EF, Alkan, SS & Pandey, N 2012, 'Larazotide acetate regulates epithelial tight junctions in vitro and in vivo', Peptides, vol. 35, no. 1, pp. 86-94. https://doi.org/10.1016/j.peptides.2012.02.015
Gopalakrishnan S, Durai M, Kitchens K, Tamiz AP, Somerville R, Ginski M et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012 May;35(1):86-94. https://doi.org/10.1016/j.peptides.2012.02.015
Gopalakrishnan, Shobha ; Durai, Malarvizhi ; Kitchens, Kelly ; Tamiz, Amir P. ; Somerville, Robert ; Ginski, Mark ; Paterson, Blake M. ; Murray, Joseph A. ; Verdu, Elena F. ; Alkan, Sefik S. ; Pandey, Niranjan. / Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. In: Peptides. 2012 ; Vol. 35, No. 1. pp. 86-94.
@article{ca89a1ffbca84faa82bdbe42b1fc382a,
title = "Larazotide acetate regulates epithelial tight junctions in vitro and in vivo",
abstract = "Tight junctions (TJs) control paracellular permeability and apical-basolateral polarity of epithelial cells, and can be regulated by exogenous and endogenous stimuli. Dysregulated permeability is associated with pathological conditions, such as celiac disease and inflammatory bowel disease. Herein we studied the mechanism by which larazotide acetate, an 8-mer peptide and TJ regulator, inhibits the cellular changes elicited by gliadin fragments, AT-1002, and cytokines. Previously, we demonstrated that AT-1002, a 6-mer peptide derived from the Vibrio cholerae zonula occludens toxin ZOT, caused several biochemical changes in IEC6 and Caco-2 cells resulting in decreased transepithelial electrical resistance (TEER) and increased TJ permeability. In this study, larazotide acetate inhibited the redistribution and rearrangement of zonula occludens-1 (ZO-1) and actin caused by AT-1002 and gliadin fragments in Caco-2 and IEC6 cells. Functionally, larazotide acetate inhibited the AT-1002-induced TEER reduction and TJ opening in Caco-2 cells. Additionally, larazotide acetate inhibited the translocation of a gliadin 13-mer peptide, which has been implicated in celiac disease, across Caco-2 cell monolayers. Further, apically applied larazotide acetate inhibited the increase in TJ permeability elicited by basolaterally applied cytokines. Finally, when tested in vivo in gliadin-sensitized HLA-HCD4/DQ8 double transgenic mice, larazotide acetate inhibited gliadin-induced macrophage accumulation in the intestine and preserved normal TJ structure. Taken together, our data suggest that larazotide acetate inhibits changes elicited by AT-1002, gliadin, and cytokines in epithelial cells and preserves TJ structure and function in vitro and in vivo.",
keywords = "Actin, Celiac disease, Gliadin, Permeability inducer, Tight junction, ZO-1",
author = "Shobha Gopalakrishnan and Malarvizhi Durai and Kelly Kitchens and Tamiz, {Amir P.} and Robert Somerville and Mark Ginski and Paterson, {Blake M.} and Murray, {Joseph A.} and Verdu, {Elena F.} and Alkan, {Sefik S.} and Niranjan Pandey",
year = "2012",
month = "5",
doi = "10.1016/j.peptides.2012.02.015",
language = "English (US)",
volume = "35",
pages = "86--94",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Larazotide acetate regulates epithelial tight junctions in vitro and in vivo

AU - Gopalakrishnan, Shobha

AU - Durai, Malarvizhi

AU - Kitchens, Kelly

AU - Tamiz, Amir P.

AU - Somerville, Robert

AU - Ginski, Mark

AU - Paterson, Blake M.

AU - Murray, Joseph A.

AU - Verdu, Elena F.

AU - Alkan, Sefik S.

AU - Pandey, Niranjan

PY - 2012/5

Y1 - 2012/5

N2 - Tight junctions (TJs) control paracellular permeability and apical-basolateral polarity of epithelial cells, and can be regulated by exogenous and endogenous stimuli. Dysregulated permeability is associated with pathological conditions, such as celiac disease and inflammatory bowel disease. Herein we studied the mechanism by which larazotide acetate, an 8-mer peptide and TJ regulator, inhibits the cellular changes elicited by gliadin fragments, AT-1002, and cytokines. Previously, we demonstrated that AT-1002, a 6-mer peptide derived from the Vibrio cholerae zonula occludens toxin ZOT, caused several biochemical changes in IEC6 and Caco-2 cells resulting in decreased transepithelial electrical resistance (TEER) and increased TJ permeability. In this study, larazotide acetate inhibited the redistribution and rearrangement of zonula occludens-1 (ZO-1) and actin caused by AT-1002 and gliadin fragments in Caco-2 and IEC6 cells. Functionally, larazotide acetate inhibited the AT-1002-induced TEER reduction and TJ opening in Caco-2 cells. Additionally, larazotide acetate inhibited the translocation of a gliadin 13-mer peptide, which has been implicated in celiac disease, across Caco-2 cell monolayers. Further, apically applied larazotide acetate inhibited the increase in TJ permeability elicited by basolaterally applied cytokines. Finally, when tested in vivo in gliadin-sensitized HLA-HCD4/DQ8 double transgenic mice, larazotide acetate inhibited gliadin-induced macrophage accumulation in the intestine and preserved normal TJ structure. Taken together, our data suggest that larazotide acetate inhibits changes elicited by AT-1002, gliadin, and cytokines in epithelial cells and preserves TJ structure and function in vitro and in vivo.

AB - Tight junctions (TJs) control paracellular permeability and apical-basolateral polarity of epithelial cells, and can be regulated by exogenous and endogenous stimuli. Dysregulated permeability is associated with pathological conditions, such as celiac disease and inflammatory bowel disease. Herein we studied the mechanism by which larazotide acetate, an 8-mer peptide and TJ regulator, inhibits the cellular changes elicited by gliadin fragments, AT-1002, and cytokines. Previously, we demonstrated that AT-1002, a 6-mer peptide derived from the Vibrio cholerae zonula occludens toxin ZOT, caused several biochemical changes in IEC6 and Caco-2 cells resulting in decreased transepithelial electrical resistance (TEER) and increased TJ permeability. In this study, larazotide acetate inhibited the redistribution and rearrangement of zonula occludens-1 (ZO-1) and actin caused by AT-1002 and gliadin fragments in Caco-2 and IEC6 cells. Functionally, larazotide acetate inhibited the AT-1002-induced TEER reduction and TJ opening in Caco-2 cells. Additionally, larazotide acetate inhibited the translocation of a gliadin 13-mer peptide, which has been implicated in celiac disease, across Caco-2 cell monolayers. Further, apically applied larazotide acetate inhibited the increase in TJ permeability elicited by basolaterally applied cytokines. Finally, when tested in vivo in gliadin-sensitized HLA-HCD4/DQ8 double transgenic mice, larazotide acetate inhibited gliadin-induced macrophage accumulation in the intestine and preserved normal TJ structure. Taken together, our data suggest that larazotide acetate inhibits changes elicited by AT-1002, gliadin, and cytokines in epithelial cells and preserves TJ structure and function in vitro and in vivo.

KW - Actin

KW - Celiac disease

KW - Gliadin

KW - Permeability inducer

KW - Tight junction

KW - ZO-1

UR - http://www.scopus.com/inward/record.url?scp=84859805588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859805588&partnerID=8YFLogxK

U2 - 10.1016/j.peptides.2012.02.015

DO - 10.1016/j.peptides.2012.02.015

M3 - Article

C2 - 22401908

AN - SCOPUS:84859805588

VL - 35

SP - 86

EP - 94

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 1

ER -